Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 3 More Generic Firms Start Voluntary Recalls of Atomoxetine Products
September 20, 2024
- Xofluza Cuts Risk of Flu Transmission in Households: PIII Data
September 20, 2024
- Asahi Kasei Pivots toward Drug Business in Healthcare to Drive Growth
September 19, 2024
- UCB CEO Hails Positive Change in Japan’s Pharma Policy
September 19, 2024
- Viatris to Discontinue Nesp Biosimilar after Global Business Sell-Off
September 19, 2024
- Asahi Kasei to Divest Medical Devices Unit to Integral, but Retains Bioprocess Biz
September 19, 2024
- Nippon Shinyaku Set to Expand Capricor DMD Therapy Pact to Europe
September 19, 2024
- AnGes’s Gene Therapy Collategene Gets FDA Breakthrough Therapy Tag
September 19, 2024
- Pfizer to Roll Out JN.1-Adapted COVID Vaccine
September 19, 2024
- J-TEC Prepping to File for Allogeneic Cultured Epidermis, Eyes Overseas Export
September 19, 2024
- Enhertu Effective in HER2 Breast Cancer with Brain Metastases
September 18, 2024
- Daiichi Sankyo’s HER3 ADC Hits PFS Goal in EGFR-Mutant Lung Cancer
September 18, 2024
- Lenvima/Keytruda Added to TACE Extend PFS in HCC
September 18, 2024
- Kissei’s Fibroid Drug Linzagolix Hits German Market
September 18, 2024
- GSK’s Multiple Myeloma Drug Blenrep Filed in Japan
September 18, 2024
- Sandoz Now Distributor of FKB’s Humira Biosimilar in Japan
September 18, 2024
- MSD Files Belzutifan for von Hippel-Lindau Disease in Japan
September 18, 2024
- Japan’s 1st Tick-Borne Encephalitis Vaccine Now Available: Pfizer
September 17, 2024
- Taisho Seeks Japan Nod for Insomnia Med Vornorexant
September 13, 2024
- Opdivo-Yervoy Filed for 1st Line Use in MSI-H Colorectal Cancer in Japan
September 13, 2024
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…